Human Papillomavirus Infections are Common and Predict Mortality in a Retrospective Cohort Study of Taiwanese Patients With Oral Cavity Cancer.

Medicine (Baltimore)

From the Department of Otorhinolaryngology, Head and Neck Surgery, Head and Neck Oncology Group (LAL, CTL, CJK, KPC, SFH, IHC, TJF, HYL); Department of Laboratory Medicine, Linkou-Chang Gung Memorial Hospital (CGH, KCT, SLY); Department of Medical Biotechnology and Laboratory Science, Graduate Insti

Published: November 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Human papillomavirus (HPV) infections are deemed to play a role in the pathogenesis of oral cavity cancer (OCC). However, their exact prevalence and clinical significance remain unclear. Herein, we investigated the prevalence and prognostic value of HPV infections in a large sample of Taiwanese OCC patients.This study was designed as a retrospective cohort study. Between 2004 and 2011, we identified 1002 consecutive patients with newly diagnosed OCC who were scheduled for standard treatment. HPV genotyping was performed in tumor specimens using polymerase chain reaction-based HPV blots. To investigate the temporal trends of HPV infections and their impact on 5-year overall survival (OS), patients were divided into 2 cohorts according to calendar periods: "2004 cohort" (2004-2007; n = 466) and "2008 cohort" (2008-2011; n = 536). Univariate and multivariate Cox regression models were also used to identify the independent predictors of OS in the 2 cohorts. A weighted risk score was assigned to each factor based on the range of their corresponding hazard ratios and validated in both cohorts using the c-statistic.The overall prevalence of HPV infections was 19%, with a trend toward decreasing rates from 2004 to 2011. In patients without risky oral habits, the 5-year OS rate of HPV-positive patients was significantly lower than that of HPV-negative cases (49% vs 80%; P = 0.021). In the 2004 cohort, multivariate analysis identified HPV16, pathological T3/T4, pathological N1/N2, and extracapsular spread as independent adverse prognostic factors for OS. In the 2008 cohort, pathological N1/N2, pathological stage III/IV, and histological tumor depth >8 mm were identified as independent adverse prognostic factors. Using a weighted grading system incorporating HPV16 infection, we devised a prognostic index that identified 4 distinct risk categories with 5-year OS rates ranging from 25% to 89% (c-statistic = 0.76) in the 2004 cohort. The validity of the index was internally confirmed in the 2008 cohort (c-statistic = 0.71).We conclude that HPV infections are common in Taiwanese OCC patients and predict 5-year OS. If independently validated, our composite prognostic score comprising HPV16 infection may be useful for allocating OCC patients to risk-adapted therapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058981PMC
http://dx.doi.org/10.1097/MD.0000000000002069DOI Listing

Publication Analysis

Top Keywords

hpv infections
20
human papillomavirus
8
infections common
8
retrospective cohort
8
cohort study
8
oral cavity
8
cavity cancer
8
taiwanese occ
8
2004 2011
8
2004 cohort
8

Similar Publications

Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..

Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.

View Article and Find Full Text PDF

[Between gender and health technologies: an analysis of HPV and cervical cancer prevention campaigns from 2014 to 2020].

Cien Saude Colet

August 2025

Instituto de Medicina Social Hesio Cordeiro, Universidade do Estado do Rio de Janeiro. R. São Francisco Xavier 524, Maracanã. 20550-900 Rio de Janeiro RJ Brasil.

In this article an analysis of the preventive campaigns against cervical cancer (CC) and human papillomavirus (HPV) vaccination developed by the National Cancer Institute (INCA) of the Ministry of Health was conducted, in addition to some campaigns produced by non-governmental organizations and private institutions, from 2014 to 2020. From a socio-anthropological point of view, the objective was to understand how these health technologies trigger and produce gender representations. Seven categories of analysis were developed ("Generationality of care", "Schooling", "Childhood and Youth", "Gamification", "Health risk", "Men's health" and "Neutrality") that permitted discussion of the themes that emerged in graphic pieces.

View Article and Find Full Text PDF

Introduction: Human papillomavirus (HPV) infection has been implicated in autoimmune processes, yet concerns remain about the potential autoimmune risks of HPV vaccination. Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that typically manifests in childhood. The relationship between HPV vaccination and the development of JIA remains uncertain.

View Article and Find Full Text PDF

Combined therapy for LSIL with HR-HPV: CO laser and interferon α2a.

Eur J Obstet Gynecol Reprod Biol

September 2025

Gynecology Department, Jiaxing Hospital of Traditional Chinese Medicine, China. Electronic address:

Objectives: Low-grade squamous intraepithelial lesions (LSIL) and high-risk human papillomavirus (HR-HPV) infection are precursors to cervical cancer. Although interferon α2a is widely used for treating HR-HPV infections, the efficacy of its combination with carbon dioxide (CO) laser therapy remains unclear.

Methods: This retrospective study included 230 patients diagnosed with LSIL and HR-HPV infection from October 2021 to August 2023.

View Article and Find Full Text PDF

Purpose: Early detection of HPV-associated oropharyngeal cancer (HPV+OPSCC), the most common HPV cancer in the United States, could reduce disease-related morbidity and mortality, yet currently, there are no early detection tests. Circulating tumor HPV DNA (ctHPVDNA) is a sensitive and specific biomarker for HPV+OPSCC at diagnosis. It is unknown if ctHPVDNA is detectable prior to diagnosis, and thus it's potential as an early detection test.

View Article and Find Full Text PDF